Conversion from Calcineurin Inhibitor to Sirolimus for Renal Function Deterioration in Kidney Allograft Recipients

BackgroundCalcineurin inhibitors play an important role in chronic allograft dysfunction. Sirolimus is an interesting alternative in renal transplant patients because it is less nephrotoxic than calcineurin inhibitors.MethodsA chart review of the clinical outcome of kidney transplant patients converted to sirolimus with progressive allograft dysfunction is reported herein. Fifteen patients (average age: 32.3 years, 44 months mean time of conversion) were included. Indication for conversion was a >20% increase in serum creatinine over the last 6 months or progression to the range of 2–4.5 mg/dL. Patients underwent abrupt cessation of cyclosporine and sirolimus addition at 2–5 mg/day.ResultsConcomitant immunosuppression remained unchanged during conversion. Targeted sirolimus level was 8–12 ng/mL. Serum creatinine dropped from pre-conversion level of 2.75 ± 0.83 to 2.14 ± 0.67 and 1.97 ± 0.66 mg/dL at 3 and 6 months (p <0.05). There was a significant decrease in blood urea nitrogen, hemoglobin and serum calcium at 3 months post-conversion as well as serum calcium and potassium at 6 months post-conversion (p <0.05). There were no rejection episodes. Patient and graft survival was 100% with three infectious complications.ConclusionsMonitored sirolimus conversion with sharp withdrawal of calcineurin inhibitor is an alternative for patients with deteriorating renal function and chronic allograft nephropathy.